Phase 0 Clinical Chemoprevention Trial of the AKT Inhibitor SR13668

PURPOSE: SR13668, an orally active AKT pathway inhibitor, has demonstrated cancer chemopreventive potential in preclinical studies. To accelerate the clinical development of this promising agent, we designed and conducted the first-ever phase 0 chemoprevention trial to evaluate and compare the effec...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Reid, Joel M., Walden, Chad, Qin, Rui, Allen Ziegler, Katie L., Haslam, John L., Rajewski, Roger A., Warndahl, Roger, Fitting, Cindy L., Boring, Daniel, Szabo, Eva, Crowell, James, Perloff, Marjorie, Jong, Ling, Mandrekar, Sumithra J., Ames, Matthew M., Limburg, Paul J.
格式: Artigo
語言:Inglês
出版: 2011
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC3061470/
https://ncbi.nlm.nih.gov/pubmed/21372034
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-10-0313
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍